Thrombocytopenic purpura with depot medroxyprogesterone acetate and subsequent use of contraceptive implant: making decisions in the absence of evidence.
Holman
Ruth
R
Department of Sexual Health, Ayrshire Central Hospital, Irvine, UK. ruth.holman@aapct.scot.nhs.uk
Stephen
Gillian
G
D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage*; D003657:Decision Making; D017135:Desogestrel / Q000008:administration & dosage*; D004343:Drug Implants; D005193:Family Planning Services / Q000379:methods; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects*; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced*; D012307:Risk Factors
D003271:Contraceptive Agents, Female; D003280:Contraceptives, Oral, Synthetic; D004343:Drug Implants; C044815:etonogestrel; D017135:Desogestrel; D017258:Medroxyprogesterone Acetate